{
    "organizations": [],
    "uuid": "5daff284b9117f98336d7b3307600d949adebed1",
    "author": "",
    "url": "https://www.reuters.com/article/brief-synlogic-doses-first-patient-in-ph/brief-synlogic-doses-first-patient-in-phase-1b-2a-trial-of-synb1020-for-treatment-of-hyperammonemia-in-patients-with-cirrhosis-idUSASC09UEH",
    "ord_in_thread": 0,
    "title": "BRIEF-Synlogic Doses First Patient In Phase 1b/2a Trial Of SYNB1020 For Treatment Of Hyperammonemia In Patients With Cirrhosis",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Market News April 2, 2018 / 11:09 AM / Updated 12 minutes ago BRIEF-Synlogic Doses First Patient In Phase 1b/2a Trial Of SYNB1020 For Treatment Of Hyperammonemia In Patients With Cirrhosis Reuters Staff 1 Min Read \nApril 2 (Reuters) - Synlogic Inc: \n* SYNLOGIC DOSES FIRST PATIENT IN PHASE 1B/2A TRIAL OF SYNB1020 FOR TREATMENT OF HYPERAMMONEMIA IN PATIENTS WITH CIRRHOSIS Source text for Eikon: Further company coverage:",
    "published": "2018-04-02T14:06:00.000+03:00",
    "crawled": "2018-04-02T14:26:18.012+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "market",
        "news",
        "april",
        "updated",
        "minute",
        "ago",
        "dos",
        "first",
        "patient",
        "phase",
        "trial",
        "synb1020",
        "treatment",
        "hyperammonemia",
        "patient",
        "cirrhosis",
        "reuters",
        "staff",
        "min",
        "read",
        "april",
        "reuters",
        "synlogic",
        "inc",
        "synlogic",
        "dos",
        "first",
        "patient",
        "phase",
        "trial",
        "synb1020",
        "treatment",
        "hyperammonemia",
        "patient",
        "cirrhosis",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}